SHUTTLE PHARMACEUTICALS HOLD

SHPHNASDAQ

🏆 #4353 by market capUS Equity

$4.31▲ $0.25 (+5.90%)

Market closed · at close

1h—

24h▲ 5.9%

7d▼ 6.1%

14d▲ 61.7%

30d▲ 33.9%

1y▼ 87.5%

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $4.25 – $4.35
52-Week Range: $2.58 – $55.90
Volume: $2.92B
Avg Volume: $2.23B
Shares Outstanding: 585,129
Next Earnings: Sep 21, 2026

Fundamentals Snapshot

Annual Revenue: $219,296
Last Q Revenue: $57,690
P/E Ratio: -0.1
P/S Ratio: 0.0x
EPS (TTM): $-21.51
Dividend Yield: 0.00%

Why Investors Own SHPH

✓High-growth profile — revenue up +30.7% YoY with expanding US Equity exposure.
✓Healthy economics — 59% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$219,296▲ +29.3% YoY

Gross Margin (TTM)

59.4%▲ +0.4% YoY

Operating Income (TTM)

$25,219▲ +29.3% YoY

Free Cash Flow (TTM)

$12,719▲ +29.3% YoY

About SHUTTLE PHARMACEUTICALS HOLD

Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.

🦦